Here, we evaluated the effect of MS-275, an inhibitor of HDAC1/3, on the degradation of hepatic LDs and FFA oxidation in HFD-induced NAFLD mice. This evidence concerns the gene HDAC1 and metabolic dysfunction-associated steatotic liver disease.